Search Results

You are looking at 71 - 80 of 128 items for :

  • "papillary" x
  • Refine by Access: All x
Clear All
Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder

less common cell types include papillary, chromophobe, and Bellini duct (collecting duct) tumors. Collecting duct carcinoma constitutes fewer than 1% of kidney cancer cases. Medullary renal carcinoma is a variant of collecting duct renal carcinoma and

Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas

that targets the hypoxia inducible factors (HIFs) for ubiquitin-mediated degradation. Mutation of the proto-oncogene MET, which codes for the hepatocyte growth factor receptor, is found in the hereditary form of type 1 papillary RCC and in a subset of

Full access

Stephanie L. Lee

. 2. Hay ID . Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma . J Surg Oncol 2006 ; 94 : 692 – 700 . 3. Verburg FA Dietlein M

Full access

Angela Jain, Paula D. Ryan, and Michael V. Seiden

markers for mOCs are more likely to be positive for CK7, CK20, and CEA, whereas only CK20 and CEA are likely to be positive for CRC. Histologically, mOCs are more likely to show a papillary growth pattern, with an expansile pattern of invasion. Metastatic

Full access

Richard S. Matulewicz, Brendan T. Frainey, Daniel T. Oberlin, and Joshua J. Meeks

timing of radical cystectomy for BCG failure: comparison of outcomes and risk factors for prognosis . J Urol 2016 ; 195 : 1704 – 1709 . 12. Patriarca C Hurle R Moschini M . Usefulness of pT1 substaging in papillary urothelial bladder

Full access

Lainie Martin and Russell J. Schilder

. Eisen T Boshoff C Mak I . Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer . Br J Cancer 2000 ; 82 : 812 – 817 . 36. Abramson N Stokes PK Luke M . Ovarian and papillary

Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman

prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of

Full access

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

rare, but have been described in cancers of the pancreas, head and neck, esophagus, biliary tract, prostate, colon, and ovaries, as well as in sarcomas and papillary renal cell carcinoma. 12 – 18 Mutations in EGFR are present in rare cases of

Full access

Michael Karass, Rohan Bareja, Ethan Shelkey, Panagiotis J. Vlachostergios, Brian D. Robinson, Francesca Khani, Juan Miguel Mosquera, Douglas S. Scherr, Andrea Sboner, Scott T. Tagawa, Ana M. Molina, Olivier Elemento, David M. Nanus, and Bishoy M. Faltas

high-grade papillary muscle-invasive UCB on repeat TURBT. Because her disease remained confined to the pelvis, she underwent a robot-assisted radical cystectomy with ileal conduit urinary diversion and left inguinal lymph node excision (pathologic stage

Full access

Tanner M. Johanns, Cole J. Ferguson, Patrick M. Grierson, Sonika Dahiya, and George Ansstas

melanoma . Cell 2015 ; 161 : 1681 – 1696 . 3. Cancer Genome Atlas Research Network . Integrated genomic characterization of papillary thyroid carcinoma . Cell 2014 ; 159 : 676 – 690 . 4. Landa I Ibrahimpasic T Boucai L